« Return to News | Drug Sponsors

Actelion to cut jobs, refocus R&D

Friday, July 13, 2012 03:17 PM

Switzerland-based Actelion has launched a cost saving initiative as an integral part of its strategy for value creation outlined in early May. The initiative will cut up to 135 positions and refocusing the company’s R&D activities toward orphan and specialty indications to generate additional specialty franchises, enabling it to fully capitalize on the significant growth opportunities in its core area of expertise of pulmonary arterial hypertension (PAH).

The cost saving initiative addresses several challenges facing the company, including the continued strength of the Swiss Franc, increased competition in the U.S., and the difficult pricing and reimbursement environment in Europe.

The refocusing of Actelion's R&D efforts is expected to result in lower and more targeted R&D spending. Following a portfolio review, those projects which are not in alignment with this strategy will be either stopped, or prepared for partnership or out-licensing. Cost savings will start to take effect in the latter part of 2012 and accelerate in 2013. The refocusing of the pipeline will require a realignment of the organization.

The cost saving initiative is expected to result in a reduction of up to 135 positions in R&D and administration. The company said it is committed to minimizing the number of potential redundancies through natural attrition, early retirements and other such measures.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.